Mirtazapine Eg

Mirtazapine, the active ingredient in Mirtazapine Eg, is a tetracyclic antidepressant presented as an oral tablet for oral use. It treats major depressive disorder in adults.\n\nGNH India supplies Mirtazapine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant indicated for depressive disorders.\n\nMajor depressive disorder: reduces depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Sedation: drowsiness or sleepiness, especially at treatment start.\n- Increased appetite and weight gain: notable rise in food intake and body weight.\n- Dry mouth: reduced salivation leading to discomfort.\n- Constipation: slowed gastrointestinal transit.\n\nSerious or Rare Side Effects:\n- Agranulocytosis or severe neutropenia: markedly reduced white‑blood‑cell count.\n- Hepatic dysfunction: elevated liver enzymes or hepatitis.\n- Suicidal thoughts or behavior: emergence of suicidal ideation, particularly early in therapy.

Before initiating therapy, several safety considerations are recommended.\n\nMonitor weight: track changes due to increased appetite.\nAssess for suicidal ideation: especially during the first weeks of treatment.\nUse caution in hepatic impairment: adjust dose if liver function is compromised.\nAvoid abrupt discontinuation: taper under medical supervision to reduce withdrawal effects.\nReview concomitant CNS depressants: risk of enhanced sedation.\nStore at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- MAO inhibitors: risk of hypertensive crisis.\n- Other serotonergic agents: potential serotonin syndrome.\n- CNS depressants: additive sedation.\n- Strong CYP2D6 inhibitors: increased mirtazapine plasma levels.\n\nModerate Interactions (Monitor Closely):\n- Alcohol: may enhance central nervous system depression.\n- Antihypertensives: possible additive blood‑pressure lowering effect.\n- Anticholinergic drugs: may worsen dry mouth and constipation.\n- Carbamazepine: may reduce mirtazapine concentrations.\n- Warfarin: occasional alteration of INR, requiring monitoring.